RAPIBLOC

This brand name is authorized in Austria, Croatia, Finland, France, Netherlands, Romania.

Active ingredients

The drug RAPIBLOC contains one active pharmaceutical ingredient (API):

1	Landiolol UNII G8HQ634Y17 - LANDIOLOL HYDROCHLORIDE
	Landiolol is a highly selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located. Landiolol, as other beta-blockers, is thought to reduce the sympathetic drive, resulting in reduction in heart rate, decrease in spontaneous firing of ectopic pacemakers, slowing the conduction and increase the refractory period of the AV node.
	Read more about Landiolol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RAPIBLOC Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AB	Beta blocking agents, selective	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents
Discover more medicines within C07AB
C07AB14		C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective
Discover more medicines within C07AB14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	060885
FR	Base de données publique des médicaments	62521323, 67004301
HR	Agencija za lijekove i medicinske proizvode	HR-H-922016446
NL	Z-Index G-Standaard, PRK	161497
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66025001, W66026001